Dr Reddy's eyes biosimilars expansion and rejigs research focus
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories is in talks with potential partners to push into regulated markets in the biosimilars segment. But the Indian firm, which claims to have sold about 1.4 million units of its biosimilar products in 12 countries so far, also says that approvals in certain emerging markets for such products are taking significantly longer than expected.